Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AstraZeneca Plc (NYSE: AZN).

Full DD Report for AZN

You must become a subscriber to view this report.


Recent News from (NYSE: AZN)

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
THOUSAND OAKS, Calif. , Sept. 6, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic ...
Source: PR Newswire
Date: September, 07 2018 02:00
Adocia's BioChaperone Pramlintide Insulin shows positive action in early-stage study in T1D
French biotech ADOCIA announces positive topline results from a Phase 1 study evaluating its BioChaperone Pramlintide Insulin in 24 patients with type 1 diabetes (T1D). More news on: Eli Lilly and Company, AstraZeneca Group plc, Merck & Co Inc., Healthcare stocks news, Read mo...
Source: SeekingAlpha
Date: September, 05 2018 12:51
PhaseBio Secures $34 Million in Series D Financing
MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the comple...
Source: GlobeNewswire
Date: September, 05 2018 08:00
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany
Stocks in News: AZN, AQST AstraZeneca's anifrolumab flunks late-stage lupus study; shares down 1% premarket Discussion: AstraZeneca ( AZN ) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE...
Source: SeekingAlpha
Date: September, 03 2018 10:43
Novo Nordisk Could Benefit From Latest FDA Warning
After the market closed on August 29, Bloomberg reported that the U.S. Food and Drug Administration issued a warning that some widely used diabetes drugs may cause a flesh-eating bacterial infection of the genitals. The drugs that are covered by the FDA's warning include Johnson & John...
Source: SeekingAlpha
Date: September, 02 2018 23:36
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516...
Source: SeekingAlpha
Date: September, 01 2018 05:42
Big Pharma in the red after AstraZeneca lupus flop
Big Pharma is getting roughed up today. This morning, AstraZeneca ( AZN -1.7% ) announced that one of its main drivers of expected future growth failed a late-stage lupus study. More news on: AstraZeneca Group plc, Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks ne...
Source: SeekingAlpha
Date: August, 31 2018 13:41
AstraZeneca's anifrolumab flunks late-stage lupus study; shares down 1% premarket
AstraZeneca (NYSE: AZN ) slips  1%  premarket on light volume in response to its announcement that a Phase 3 clinical trial, TULIP 1 , evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE) failed to achieve the primary endpoint of a ...
Source: SeekingAlpha
Date: August, 31 2018 07:10
Et Tu, Bruton?
Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales ...
Source: SeekingAlpha
Date: August, 30 2018 11:15
Your Cancer Highlight: Clovis Looks To Capture Deeper Relevance With Bristol-Myers Collab
When it comes to PARP inhibitors, the reality hasn't quite matched the initial promise. Certainly, we've seen a lot of progress in the space of ovarian cancer, where patients are experiencing a quiet revolution, including those patients who have BRCA1/2 -mutant disease. Come this time next ...
Source: SeekingAlpha
Date: August, 29 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0836.9537.1837.2436.942,167,175
2018-05-1736.6336.4436.7436.185,134,529
2017-11-0733.6133.6133.69533.384,409,593
2017-11-0634.3334.2234.3534.123,390,584
2017-11-0334.2134.4834.5434.182,924,097

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1217,85153,42833.4113Cover
2018-12-1137,01557,52664.3448Short
2018-12-1021,697104,69820.7234Cover
2018-12-0736,64980,26345.6611Short
2018-12-0634,510131,65226.2130Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AZN.


About AstraZeneca Plc (NYSE: AZN)

Logo for AstraZeneca Plc (NYSE: AZN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $23,027,175,517 - 05/11/2018
  • Issue and Outstanding: 632,614,712 - 12/31/2016

 


Recent Filings from (NYSE: AZN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 11 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 19 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018

 

 


Daily Technical Chart for (NYSE: AZN)

Daily Technical Chart for (NYSE: AZN)


Stay tuned for daily updates and more on (NYSE: AZN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: AZN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AZN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AZN and does not buy, sell, or trade any shares of AZN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/